223 related articles for article (PubMed ID: 6246008)
1. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. II. Dynamic changes during tumor progression.
Wang WC; Berczi I; Hoffmann EG; Sehon AH
Int J Cancer; 1980 Apr; 25(4):493-501. PubMed ID: 6246008
[TBL] [Abstract][Full Text] [Related]
2. Effector and enhancing lymphoid cells in plasmacytoma-bearing mice. I. Methodological studies on the Winn assay.
Wang KC; Berczi I; Sehon AH
Int J Cancer; 1980 Apr; 25(4):487-92. PubMed ID: 7372372
[TBL] [Abstract][Full Text] [Related]
3. Immunoregulation of murine plasmacytoma. I. Generation of anomalous killer cells in vitro by cocultivation with MOPC 104E.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):17-26. PubMed ID: 2567619
[TBL] [Abstract][Full Text] [Related]
4. Some characteristics of the in vivo antitumor immunity exhibited by mice cured of a large MOPC-315 tumor by a low dose of melphalan.
Barker E; Mokyr MB
Cancer Immunol Immunother; 1987; 25(3):215-24. PubMed ID: 3677124
[TBL] [Abstract][Full Text] [Related]
5. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
Nio Y; Ohgaki K; Tobe T
J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
[TBL] [Abstract][Full Text] [Related]
6. Host response to myeloma: effect of syngeneic spleen cells on the growth and function of MOPC 104E myeloma in vitro.
Miura T; Ghanta VK; Hiramoto RN
Cancer Invest; 1990; 8(1):17-25. PubMed ID: 2350718
[TBL] [Abstract][Full Text] [Related]
7. Specificity of the generation and expression of enhanced anti-plasmacytoma immunity by spleen cells from melphalan-treated MOPC-315 tumor bearers.
Mokyr MB; Barker E
Cancer Immunol Immunother; 1986; 23(1):11-9. PubMed ID: 3490305
[TBL] [Abstract][Full Text] [Related]
8. Regulation of MOPC 104E by T cells and growth factors induced by C. parvum stimulation.
Shrestha K; Hiramoto RN; Ghanta VK
Int J Cancer; 1984 Jun; 33(6):845-50. PubMed ID: 6610653
[TBL] [Abstract][Full Text] [Related]
9. Effect of low-dose cyclophosphamide therapy on specific and nonspecific T cell-dependent immune responses of spleen cells from mice bearing large MOPC-315 plasmacytomas.
Wise JA; Mokyr MB; Dray S
Cancer Immunol Immunother; 1988; 27(3):191-7. PubMed ID: 3263205
[TBL] [Abstract][Full Text] [Related]
10. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
Marsili MA; Walker MC; Phillips-Quagliata JM
Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
[TBL] [Abstract][Full Text] [Related]
11. Lysis of antigenically unrelated tumor cells mediated by Lyt 2+ splenic T-cells from melphalan-cured MOPC-315 tumor bearers.
Barker E; Wise JA; Dray S; Mokyr MB
Cancer Res; 1989 Sep; 49(18):5007-15. PubMed ID: 2788494
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of growth of MOPC 104E cells in immunosuppressed mice.
Hiramoto RN; Cox PJ; Hiramoto NS; Ghanta VK
J Immunol; 1984 Dec; 133(6):3424-8. PubMed ID: 6386985
[TBL] [Abstract][Full Text] [Related]
13. Importance of Lyt-2+ T-cells in the resistance of melphalan-cured MOPC-315 tumor bearers to a challenge with MOPC-315 tumor cells.
Barker E; Mokyr MB
Cancer Res; 1988 Sep; 48(17):4834-42. PubMed ID: 3261626
[TBL] [Abstract][Full Text] [Related]
14. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
15. Induction of tumor-specific antitumor immunity after chemotherapy with cisplatin in mice bearing MOPC-104E plasmacytoma by modulation of MHC expression on tumor surface.
Nio Y; Hirahara N; Minari Y; Iguchi C; Yamasawa K; Toga T; Tamura K
Anticancer Res; 2000; 20(5A):3293-9. PubMed ID: 11062756
[TBL] [Abstract][Full Text] [Related]
16. Two tumor models of curative adoptive chemoimmunotherapy using tumor-infiltrated spleen cells with potent antitumor cytotoxicity stimulated by antigen-sharing tumors.
Laude M; Russo KL; Mokyr MB; Dray S
Cancer Immunol Immunother; 1993 Jul; 37(2):89-96. PubMed ID: 8319246
[TBL] [Abstract][Full Text] [Related]
17. Immunoregulation of murine plasmacytoma. II. Target selectivity of anomalous killer cells and role of immune T cells for the induction.
Hayashida I; Hiramoto RN; Shrestha K; Ghanta VK
Cancer Invest; 1989; 7(1):27-38. PubMed ID: 2786740
[TBL] [Abstract][Full Text] [Related]
18. Induction of resistance or enhancement to a transplantable murine plasmacytoma by transfer of non-immune leucocytes.
Giovarelli M; Comoglio PM; Forni G
Br J Cancer; 1976 Sep; 34(3):233-8. PubMed ID: 788762
[TBL] [Abstract][Full Text] [Related]
19. Enhanced antitumor effects of bone marrow transplantation in combination with fibroblast-mediated IL-2 and IL-3 gene therapy.
Cao X; Li Q; Ju DW; Wang Q; Tao Q; Wang J
Transplantation; 1999 May; 67(9):1242-50. PubMed ID: 10342316
[TBL] [Abstract][Full Text] [Related]
20. Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan.
Mokyr MB; Rubin M; Newell KA; Prokhorova A; Bluestone JA
J Immunol; 1993 Nov; 151(9):4838-46. PubMed ID: 8409442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
